Tuya Pal1, Susan T Vadaparampil. 1. Population Sciences Department of Cancer Epidemiology, Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA. Tuya.Pal@moffitt.org
Abstract
BACKGROUND: It has become increasingly common to consider BRCA mutation status when determining optimal cancer risk management and treatment options in order to improve patient outcomes. Knowledge about the risk for hereditary cancer at or as close as possible to the time of diagnosis allows patients access to the most risk reduction options available. METHODS: This paper illustrates the role of genetic risk assessment for hereditary breast cancer, using hereditary breast and ovarian cancer (HBOC) syndrome as a model due to germline mutations in the BRCA1 and BRCA2. Specifically, the value of genetic counseling and testing for HBOC across the cancer prevention and control continuum is outlined as it pertains to breast cancer. RESULTS: In recognition of the importance of risk assessment for hereditary breast cancer, leading health professional organizations have developed specific guidelines and recommendations to providers for identification of women at increased risk for carrying a BRCA mutation. CONCLUSIONS: Institutional efforts specific to genetic counseling and testing have resulted in the implementation of a model driven by physician recommendation as a referral system for high-risk breast cancer patients. Establishing an infrastructure to support research, education, and outreach initiatives focused on BRCA genetic counseling and testing will provide information that can improve the delivery of cancer genetics services.
BACKGROUND: It has become increasingly common to consider BRCA mutation status when determining optimal cancer risk management and treatment options in order to improve patient outcomes. Knowledge about the risk for hereditary cancer at or as close as possible to the time of diagnosis allows patients access to the most risk reduction options available. METHODS: This paper illustrates the role of genetic risk assessment for hereditary breast cancer, using hereditary breast and ovarian cancer (HBOC) syndrome as a model due to germline mutations in the BRCA1 and BRCA2. Specifically, the value of genetic counseling and testing for HBOC across the cancer prevention and control continuum is outlined as it pertains to breast cancer. RESULTS: In recognition of the importance of risk assessment for hereditary breast cancer, leading health professional organizations have developed specific guidelines and recommendations to providers for identification of women at increased risk for carrying a BRCA mutation. CONCLUSIONS: Institutional efforts specific to genetic counseling and testing have resulted in the implementation of a model driven by physician recommendation as a referral system for high-risk breast cancerpatients. Establishing an infrastructure to support research, education, and outreach initiatives focused on BRCA genetic counseling and testing will provide information that can improve the delivery of cancer genetics services.
Authors: Swati Biswas; Neelam Tankhiwale; Amanda Blackford; Angelica M Gutierrez Barrera; Kaylene Ready; Karen Lu; Christopher I Amos; Giovanni Parmigiani; Banu Arun Journal: Breast Cancer Res Treat Date: 2012-01-21 Impact factor: 4.872
Authors: Marlene H Frost; Jeffrey M Slezak; Nho V Tran; Constance I Williams; Joanne L Johnson; John E Woods; Paul M Petty; John H Donohue; Clive S Grant; Jeff A Sloan; Thomas A Sellers; Lynn C Hartmann Journal: J Clin Oncol Date: 2005-10-03 Impact factor: 44.544
Authors: Steven A Narod; Jan Lubinski; Parviz Ghadirian; Henry T Lynch; Pal Moller; William D Foulkes; Barry Rosen; Charmaine Kim-Sing; Claudine Isaacs; Susan Domchek; Susan Domcheck; Ping Sun Journal: Lancet Oncol Date: 2006-05 Impact factor: 41.316
Authors: Ellen Warner; Kimberley Hill; Petrina Causer; Donald Plewes; Roberta Jong; Martin Yaffe; William D Foulkes; Parviz Ghadirian; Henry Lynch; Fergus Couch; John Wong; Frances Wright; Ping Sun; Steven A Narod Journal: J Clin Oncol Date: 2011-03-28 Impact factor: 44.544
Authors: Jeffrey N Weitzel; Kathleen R Blazer; Deborah J MacDonald; Julie O Culver; Kenneth Offit Journal: CA Cancer J Clin Date: 2011-08-19 Impact factor: 508.702
Authors: Andrea Eisen; Jan Lubinski; Jan Klijn; Pal Moller; Henry T Lynch; Kenneth Offit; Barbara Weber; Tim Rebbeck; Susan L Neuhausen; Parviz Ghadirian; William D Foulkes; Ruth Gershoni-Baruch; Eitan Friedman; Gadi Rennert; Teresa Wagner; Claudine Isaacs; Charmaine Kim-Sing; Peter Ainsworth; Ping Sun; Steven A Narod Journal: J Clin Oncol Date: 2005-10-20 Impact factor: 44.544
Authors: Kelly A Metcalfe; Daphna Birenbaum-Carmeli; Jan Lubinski; Jacek Gronwald; Henry Lynch; Pal Moller; Parviz Ghadirian; William D Foulkes; Jan Klijn; Eitan Friedman; Charmaine Kim-Sing; Peter Ainsworth; Barry Rosen; Susan Domchek; Teresa Wagner; Nadine Tung; Siranoush Manoukian; Fergus Couch; Ping Sun; Steven A Narod Journal: Int J Cancer Date: 2008-05-01 Impact factor: 7.396
Authors: T Pal; J-H Lee; A Besharat; Z Thompson; A N A Monteiro; C Phelan; J M Lancaster; K Metcalfe; T A Sellers; S Vadaparampil; S A Narod Journal: Clin Genet Date: 2013-03-21 Impact factor: 4.438
Authors: Anita Y Kinney; Rachel Howell; Rachel Ruckman; Jean A McDougall; Tawny W Boyce; Belinda Vicuña; Ji-Hyun Lee; Dolores D Guest; Randi Rycroft; Patricia A Valverde; Kristina M Gallegos; Angela Meisner; Charles L Wiggins; Antoinette Stroup; Lisa E Paddock; Scott T Walters Journal: Contemp Clin Trials Date: 2018-09-18 Impact factor: 2.226
Authors: Deborah Cragun; Anne Weidner; Courtney Lewis; Devon Bonner; Jongphil Kim; Susan T Vadaparampil; Tuya Pal Journal: Cancer Date: 2017-02-09 Impact factor: 6.860
Authors: Courtney Lynam Scherr; Kelli Nam; Bianca Augusto; Monica L Kasting; Meghan Caldwell; Marie Catherine Lee; Cathy D Meade; Tuya Pal; Gwendolyn P Quinn; Susan T Vadaparampil Journal: Health Commun Date: 2019-04-18